FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Alberta as of June 5, 2023. Please see the following link for full funding criteria: AHS Outpatient Cancer Drug Benefit Program 2023-06-05 (albertahealthservices.ca).
We are excited about this important milestone for multiple myeloma patients in Alberta.
Read on LinkedIn